Latest News for: eisai co.

Edit

Non-Small Cell Lung Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by ...

GetNews 21 Mar 2025
Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others, are developing therapies for the Non-Small Cell Lung Cancer treatment ... Qilu Pharmaceutical Co., Ltd ... Ono Pharmaceutical Co ... Eisai Inc.
Edit

Metastatic Breast Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 19 Mar 2025
Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd., Pfizer, OncoTherapy Science, Inc., Eisai ...
Edit

Lewy Body Dementia Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports ...

GetNews 19 Mar 2025
Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H ... Eisai ... Eisai Inc ... Eisai Co., Ltd ... Eisai, EIP Pharma, Sun Pharma, ...
Edit

Dementia Market Expected to Experience Major Growth by 2032, According to DelveInsight | Charsire Biotech ...

GetNews 18 Mar 2025
... Pharma, Johnson & Johnson, Materia Medica Holding, Eisai Co., Ltd., Shineway Pharma, Merz Pharma, Ever Neuro Pharma GmbH, Zhejiang Otsuka Pharma, Janssen, LP, GE Healthcare, and others ... Eisai Co., Ltd.
Edit

BRAF Mutated Non-small Cell Lung Cancer Market Predicted to See Upsurge Through 2032, Highlights DelveInsight ...

GetNews 05 Mar 2025
Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others ... Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others ... Ono Pharmaceutical Co ... Eisai Inc ... Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others.
Edit

Global Alzheimer’s Therapeutics Market Share Analysis Poised to Reach USD 4,288.82 Million by 2025 Driven by R&D Investments and Strategic Alliances | FMI

Pharmiweb 05 Mar 2025
Leading pharmaceutical firms are heavily investing in breakthrough therapeutics targeting amyloid plaques and tau proteins, the key pathological markers of Alzheimer’s disease ... Advancements in Drug Development ... Mid-sized companies, including Eisai Co ... .
Edit

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia

Pharmiweb 04 Mar 2025
TOKYO and CAMBRIDGE, Mass., March 3, 2025 – Eisai Co., Ltd ... Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority ... Eisai Co., Ltd ... Eisai Co., Ltd.
Edit

Ewing Sarcoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, ...

GetNews 03 Mar 2025
The leading Ewing Sarcoma Companies such as Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, ...
  • 1
×